Kidney, Phase III
A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Volunteers
Health Professionals
What is the purpose of this trial?
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Andrea Brennan, PA
- Benjamin Newton, MD
- Clarice Grens, APRN
- David Schoenfeld, MD, PhD
- Emily Kopas, APRN, OCN
- Harriet Kluger, MD
- Jadwiga Kretowicz, APRN
- Jason Haldas, MD
- Jeffrey Ishizuka, MD, DPhil
- Justin Persico, MD
- Larisa Fleysher, APRN
- M. Sung Lee, MD
- Marianne Davies, NP, DNP, MSN, APRN, BSN
- Matthew Austin, MD
- Michael Hurwitz, MD, PhD
- Sarah Carlson, PA
- Su Hsien Lim, MD
- Wajih Kidwai, MD, FACP
- Last Updated06/09/2026
- Study IRB#2000040936